Laserfiche WebLink
<br />C-6 <br /> <br /> <br />7. The Promotional conduct prohibited in subsection C is not prohibited insofar as it <br />relates to the Promotion of Opioids or Opioid Products for Cancer-Related Pain Care <br />or End-of-Life Care only, and so long as Janssen is identified as the sponsor or <br />source of such Promotional conduct. <br />D. No Financial Reward or Discipline Based on Volume of Opioid Sales <br />1. Janssen shall not provide financial incentives to its sales and marketing employees or <br />discipline its sales and marketing employees based upon sales volume or sales quotas <br />for Opioid Products; <br />2. Janssen shall not offer or pay any remuneration (including any kickback, bribe, or <br />rebate) directly or indirectly, to any person in return for the prescribing, sale, use, or <br />distribution of an Opioid Product; and <br />3. Janssen’s compensation policies and procedures shall ensure compliance with the <br />Agreement. <br />E. Ban on Funding/Grants to Third Parties <br />1. Janssen shall not directly or indirectly provide financial support or In-Kind Support <br />to any Third Party that primarily engages in conduct that Promotes Opioids, Opioid <br />Products, or Products for the Treatment of Opioid-induced Side Effects (subject to <br />subsections C.2, 4, and 6), including educational programs or websites that Promote <br />Opioids, Opioid Products, or products for the treatment of Opioid-induced side <br />effects, excluding financial support otherwise required by the Agreement, a court <br />order, or by a federal or state agency. <br />2. Janssen shall not create, sponsor, provide financial support or In-Kind Support to, or <br />otherwise operate or control any medical society or patient advocacy group that <br />primarily engages in conduct that Promotes Opioids, Opioid Products, or products <br />for the treatment of Opioid-induced side effects. <br />3. Janssen shall not provide links to any Third Party website or materials or otherwise <br />distribute materials created by a Third Party for the purpose of Promoting Opioids, <br />Opioid Products, or products intended for the treatment of Opioid-induced side <br />effects (subject to subsections C.2, 4, and 6). <br />4. Janssen shall not use, assist, or employ any Third Party to engage in any activity that <br />Janssen itself would be prohibited from engaging in pursuant to the Agreement. To <br />the extent Janssen supports trade groups engaged in Lobbying, Janssen shall stipulate <br />that such support not be used for any purpose prohibited by the Agreement. <br />5. Janssen shall not enter into any contract or agreement with any person or entity or <br />otherwise attempt to influence any person or entity in such a manner that has the <br />purpose or foreseeable effect of limiting the dissemination of information regarding <br />the risks and side effects of using Opioids.